Results 21 to 30 of about 98,565 (232)
Fucoidan is a novel platelet agonist for the C-type lectin-like receptor 2 (CLEC-2). [PDF]
Fucoidan, a sulfated polysaccharide from Fucus vesiculosus, decreases bleeding time and clotting time in hemophilia, possibly through inhibition of tissue factor pathway inhibitor. However, its effect on platelets and the receptor by which fucoidan induces cellular processes has not been elucidated.
Manne BK +7 more
europepmc +4 more sources
C-type lectin like receptor 2 (CLEC-2) signals independently of lipid raft microdomains in platelets. [PDF]
C-type lectin like receptor 2 (CLEC-2) has been reported to activate platelets through a lipid raft-dependent manner. Secreted ADP potentiates CLEC-2-mediated platelet aggregation. We have investigated whether the decrease in CLEC-2-mediated platelet aggregation, previously reported in platelets with disrupted rafts, is a result of the loss of agonist ...
Manne BK +3 more
europepmc +4 more sources
Gq pathway regulates proximal C-type lectin-like receptor-2 (CLEC-2) signaling in platelets. [PDF]
Platelets play a key role in the physiological hemostasis or pathological process of thrombosis. Rhodocytin, an agonist of the C-type lectin-like receptor-2 (CLEC-2), elicits powerful platelet activation signals in conjunction with Src family kinases (SFKs), spleen tyrosine kinase (Syk), and phospholipase γ2 (PLCγ2).
Badolia R +5 more
europepmc +4 more sources
Objectives: The main purpose of the study was to study the association between circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels and various markers, including inflammatory markers such as high-sensitivity C-reactive ...
Kohzo Takebayashi +6 more
doaj +1 more source
Platelet C-Type Lectin-Like Receptor 2 Reduces Cholestatic Liver Injury in Mice [PDF]
Cholestatic liver injury leads to liver dysfunction. The available evidence suggests that platelets can either promote or reduce liver injury and fibrosis. This study focused on the functions of the C-type lectin-like receptor 2 (CLEC-2), a new special platelet receptor that binds with podoplanin-activating platelets.
Suguru, Maruyama +15 more
openaire +2 more sources
The SARS-CoV-2 virion has shown remarkable resilience, capable of mutating to escape immune detection and re-establishing infectious capabilities despite new vaccine rollouts.
Arjan Bains +2 more
doaj +1 more source
Objectives To assess the association between plasma C-type lectin-like receptor 2 (CLEC-2) and ST elevation myocardial infarction (STEMI) and its correlation with clinicolaboratory data.
Salwa Hassan Ahmed +4 more
doaj +1 more source
Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists
Fluorescence correlation spectroscopy on crosslinked nanobodies tested on C-type lectin-like receptor 2 (CLEC-2) show different outcomes for divalent and tetravalent nanobody ligands on CLEC-2 clustering, also dependent on CLEC-2 expression levels.
Joanne C. Clark +16 more
doaj +1 more source
Abnormalities in C-type lectin-like receptor 2 in a patient with Gorham-Stout disease: the first case report. [PDF]
Gorham-Stout disease (GSD) is a form of lymphangiomatosis of unknown etiology, characterized by abnormal distribution of lymphatic vessels. Platelets and lymphangiogenesis are closely related via C-type lectin-like receptor 2 (CLEC-2)/podoplanin.Despite similarities between abnormal lymphatic vessels in CLEC-2-deficient mice and patients with GSD ...
Oishi S +5 more
europepmc +3 more sources
Kappa-carrageenan (KCG), which is used to induce thrombosis in laboratory animals for antithrombotic drug screening, can trigger platelet aggregation. However, the cell-surface receptor and related signaling pathways remain unclear.
Ryohei Yokomori +6 more
doaj +1 more source

